<DOC>
	<DOCNO>NCT01308996</DOCNO>
	<brief_summary>The purpose study evaluate INFUSE® Bone Graft alternative autograft bone formation back mandible ( low jaw ) prior place dental implant .</brief_summary>
	<brief_title>Clinical Study INFUSE® Bone Graft Compared Autogenous Bone Graft Vertical Ridge Augmentation</brief_title>
	<detailed_description>The purpose study evaluate INFUSE® Bone Graft alternative autograft alveolar ridge bone formation posterior mandible prior dental implant . A subject must defect behind canine 2-4 teeth least 2 month candidate dental implant .</detailed_description>
	<mesh_term>Mouth , Edentulous</mesh_term>
	<mesh_term>Alveolar Bone Loss</mesh_term>
	<criteria>1 . Has edentulous least 2 month alveolar ridge defect affect 24 teeth posterior mandible , posterior canine . 2 . Has alveolar ridge defect minimum start height 5 mm superior cortex inferior alveolar canal posterior mandible . 3 . Is candidate dental implant ( 24 teeth ) affect posterior mandibular alveolar ridge area . 4 . Has prosthodontic treatment plan place . 5 . Has know condition would interfere collect autogenous bone either tibia iliac crest bone graft procedure . 6 . Is 2175 year age ( inclusive ) . 7 . If female childbearing potential , negative urine pregnancy test , lactating , agree become pregnant least 12 month surgery . 8 . Is able comply studyrelated procedure , include exercise good oral hygiene . 9 . Is able provide write informed consent . 1 . Has bilateral alveolar ridge defect require simultaneous augmentation second augmentation plan course study . 2 . Has active infection plan augmentation site . 3 . Has active periodontal disease Grade III high . 4 . Has dental extraction procedure plan augmentation site within 2 month prior Day 0 . 5 . Has soft tissue graft plan augmentation site within less 2 week Screening . 6 . Is expect require additional bone graft material ( e.g. , allograft xenograft ) plan augmentation site addition investigative treatment autogenous bone , determine investigator prior surgery . 7 . Has history fail alveolar ridge augmentation procedure . 8 . Has pathology find would either compromise bone graft procedure interfere obtain quantitative measurement postoperative CT scan . 9 . Is insulindependent diabetic . 10 . Has overt active systemic infection , human immunodeficiency virus ( HIV ) , bacteremia , hepatitis C virus ( HCV ) . 11 . Has plan augmentation site area resect extant tumor . 12 . Has presence active malignancy prior history malignancy ( except basal cell carcinoma skin ) . 13 . Is actively use nicotinecontaining product , limited , smoke chew tobacco , nicotine patch , nicotine gum , etc . within 2 week prior Screening . 14 . Is alcohol drug dependent , determine investigator . 15 . Is take medication treatment know effect bone metabolism , , limit : calcitonin within past 6 month ; fluorides 30 day within past 12 month ; cumulative use oral bisphosphonates less 5 year within past 6 month ; cumulative use oral bisphosphonates 5 year ; previous use intravenous bisphosphonates ; chronic tetracycline ( e.g. , ongoing within past month ) tetracycline analog within past 12 month ; estrogen replacement therapy within past 2 month ; methotrexate within past 12 month . 16 . Has disease affect bone metabolism , : congenital connective tissue disease ( e.g. , EhlersDanlos syndrome , osteogenesis imperfecta ) ; hyperthyroidism ; hyperparathyroidism . 17 . Has history autoimmune disease ( e.g. , systemic lupus erythematosus , dermatomyositis , rheumatoid arthritis , etc. ) . 18 . Has previous exposure recombinant BMPs either human animal extraction . 19 . Has know history prior exposure silicone injectable collagen implant . 20 . Has know hypersensitivity allergy collagen protein pharmaceutical ( e.g. , monoclonal antibody gamma globulin ) . 21 . Has know hypersensitivity allergy titanium . 22 . Has history allergy bovine collagen product . 23 . Has chronic acute renal failure 24 . Has chronic acute liver failure . 25 . Has receive treatment investigational therapy ( drug , device , and/or biologic ) within 30 day prior bone graft implantation surgery treatment plan 12month period follow study surgery . 26 . Has condition judgment investigator would place subject undue risk interfere result study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>alveolar ridge augmentation</keyword>
	<keyword>edentulous ridge</keyword>
	<keyword>alveolar ridge defect</keyword>
	<keyword>posterior mandible defect</keyword>
	<keyword>bone morphogenic protein</keyword>
	<keyword>osseointegration</keyword>
</DOC>